GATA3 and breast cancer: The discovery that loss of GATA3, a critical factor for luminal lineage determination during breast epithelial differentiation [36,39], can drive tumorigenesis in experimental models [37,38] and correlates with poor prognosis in breast cancer patients [40,45,46,51] justifiably prompted its consideration as a tumor suppressor, as well as expectations that new therapeutic strategies could be devised to induce differentiated features in breast cancer cells [52].